IT1250064B - Immunoglobuline purificate, procedimento per la loro purificazione e loro impiego per la preparazione di medicinali. - Google Patents

Immunoglobuline purificate, procedimento per la loro purificazione e loro impiego per la preparazione di medicinali.

Info

Publication number
IT1250064B
IT1250064B ITRM910788A ITRM910788A IT1250064B IT 1250064 B IT1250064 B IT 1250064B IT RM910788 A ITRM910788 A IT RM910788A IT RM910788 A ITRM910788 A IT RM910788A IT 1250064 B IT1250064 B IT 1250064B
Authority
IT
Italy
Prior art keywords
preparation
reducing conditions
purification
procedure
medicinal products
Prior art date
Application number
ITRM910788A
Other languages
English (en)
Italian (it)
Inventor
Paul Ian Nicholas Ramage
Geoffrey Allen
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10683866&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IT1250064(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of ITRM910788A0 publication Critical patent/ITRM910788A0/it
Publication of ITRM910788A1 publication Critical patent/ITRM910788A1/it
Application granted granted Critical
Publication of IT1250064B publication Critical patent/IT1250064B/it

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065Purification, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ITRM910788A 1990-10-17 1991-10-16 Immunoglobuline purificate, procedimento per la loro purificazione e loro impiego per la preparazione di medicinali. IT1250064B (it)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909022547A GB9022547D0 (en) 1990-10-17 1990-10-17 Purified immunoglobulin

Publications (3)

Publication Number Publication Date
ITRM910788A0 ITRM910788A0 (it) 1991-10-16
ITRM910788A1 ITRM910788A1 (it) 1993-04-16
IT1250064B true IT1250064B (it) 1995-03-30

Family

ID=10683866

Family Applications (1)

Application Number Title Priority Date Filing Date
ITRM910788A IT1250064B (it) 1990-10-17 1991-10-16 Immunoglobuline purificate, procedimento per la loro purificazione e loro impiego per la preparazione di medicinali.

Country Status (29)

Country Link
US (1) US5644036A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0504363B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2638680B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (2) KR960015399B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (2) ATA900791A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (3) AU658926B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE1004226A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR1100358A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2069481C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH (2) CH681455A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69128774T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0504363T4 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (2) ES2081742B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (2) FI110003B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (2) FR2668164A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (2) GB9022547D0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (3) GR910100425A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUT64601A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE913560A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (3) IL102726A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IT (1) IT1250064B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LU88122A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX9203794A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (2) MY136210A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (2) NZ240247A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (2) PT99248B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW283710B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1992007084A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (2) ZA926191B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
DK0610447T3 (da) * 1991-10-15 1999-08-23 Btg Int Ltd CDw52-specifikt antistof til behandling af T-cellemedieret inflammation af leddene
GB9125768D0 (en) * 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
GB9300501D0 (en) * 1993-01-09 1993-03-03 Wellcome Found Purification of immunoglobulin
EP0841942B2 (fr) 1995-08-01 2007-12-12 Sanofi Pasteur Procede de production industrielle d'un vaccin contre l'encephalite japonaise et vaccin obtenu
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
CZ292465B6 (cs) * 1996-02-09 2003-09-17 Abbott Laboratories (Bermuda) Ltd. Lidské protilátky k lidskému TNFalfa
GB9603256D0 (en) * 1996-02-16 1996-04-17 Wellcome Found Antibodies
US20030023043A1 (en) * 2000-03-02 2003-01-30 Kazuhisa Uchida Method of separating and purifying protein
EP2336149A1 (en) 2001-03-09 2011-06-22 Chugai Seiyaku Kabushiki Kaisha Protein purification method
ATE421536T1 (de) * 2001-06-05 2009-02-15 Genetics Inst Llc Verfahren zur reinigung stark anionischer proteine
GB0220894D0 (en) * 2002-09-09 2002-10-16 Millipore Uk Ltd Method of separation
DK2261230T3 (en) 2002-09-11 2017-06-12 Chugai Pharmaceutical Co Ltd Method of Protein Purification.
JP5116971B2 (ja) 2002-10-15 2013-01-09 インターセル アーゲー B群連鎖球菌の接着因子をコードする核酸、b群連鎖球菌の接着因子、およびその使用
GB0304576D0 (en) * 2003-02-28 2003-04-02 Lonza Biologics Plc Protein a chromatography
BRPI0417993A (pt) * 2003-12-22 2007-04-27 Genzyme Corp anticorpo anti-cd52 para tratamento da diabetes
SI1869065T1 (sl) * 2005-03-11 2020-08-31 Wyeth Llc Postopek kromatografije z nizko porazdelitvijo
EP4368721A3 (en) 2007-09-26 2024-12-18 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
SI2708559T1 (en) 2008-04-11 2018-07-31 Chugai Seiyaku Kabushiki Kaisha An antigen-binding molecule capable of repeatably binding to two or more antigenic molecules
SG10201608169QA (en) 2009-05-13 2016-11-29 Genzyme Corp Anti-human cd52 immunoglobulins
CA2761885A1 (en) 2009-05-13 2010-11-18 Genzyme Corporation Methods and compositions for treating lupus
EP2519536A4 (en) * 2009-12-29 2013-06-05 Reddys Lab Ltd Dr PROTEIN PURIFICATION BY ION EXCHANGE
JP5873016B2 (ja) 2010-06-21 2016-03-01 協和発酵キリン株式会社 アミノ酸を利用したタンパク質の精製方法
RU2467783C2 (ru) * 2010-07-30 2012-11-27 Закрытое акционерное общество "БиоХимМак СТ" Способ хроматографического выделения иммуноглобулина
TWI761912B (zh) 2010-11-30 2022-04-21 日商中外製藥股份有限公司 具有鈣依存性的抗原結合能力之抗體
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
GB201109238D0 (en) * 2011-06-01 2011-07-13 Antitope Ltd Antibodies
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9650411B2 (en) 2012-08-07 2017-05-16 Kyowa Hakko Kirin Co., Ltd. Method of purifying protein
US9206390B2 (en) 2012-09-02 2015-12-08 Abbvie, Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
AU2013381687A1 (en) 2013-03-12 2015-09-24 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
AU2013203043B2 (en) 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
MY181081A (en) 2013-12-27 2020-12-17 Chugai Pharmaceutical Co Ltd Method for purifying antibody having low isoelectric point
AR103161A1 (es) 2014-12-19 2017-04-19 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso
JP6823596B2 (ja) 2015-07-31 2021-02-03 中外製薬株式会社 アニオン性ポリマーによる抗体を含有する組成物の精製方法
JP7141336B2 (ja) 2015-12-25 2022-09-22 中外製薬株式会社 抗ミオスタチン抗体および使用方法
KR102359192B1 (ko) 2016-07-25 2022-02-04 세파론, 인코포레이티드 친화성 크로마토그래피 세정 완충액
WO2018025982A1 (ja) 2016-08-05 2018-02-08 中外製薬株式会社 Il-8関連疾患の治療用又は予防用組成物
EP3950099A4 (en) 2019-03-29 2022-05-18 Asahi Kasei Medical Co., Ltd. Method for purifying protein
US12383884B2 (en) 2019-04-08 2025-08-12 Asahi Kasei Medical Co., Ltd. Polyamide medium for purifying protein-containing solution and method for producing polyamide medium
JP7583411B2 (ja) 2019-04-10 2024-11-14 中外製薬株式会社 Fc領域改変抗体の精製方法
WO2022260091A1 (ja) 2021-06-10 2022-12-15 三菱ケミカル株式会社 合成吸着剤、抗体の精製方法及び抗体の製造方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118796A (en) * 1987-12-09 1992-06-02 Centocor, Incorporated Efficient large-scale purification of immunoglobulins and derivatives
CA1339198C (en) * 1988-02-12 1997-08-05 Gregory Paul Winter Antibodies to the antigen campath-1

Also Published As

Publication number Publication date
ES2081742B1 (es) 1996-10-01
KR920703108A (ko) 1992-12-17
PT100988A (pt) 1994-02-28
DK0504363T4 (da) 2007-05-29
IL99761A0 (en) 1992-08-18
BR1100358A (pt) 2000-03-28
KR100193314B1 (ko) 1999-06-15
MX9203794A (es) 1992-07-01
BE1004226A5 (fr) 1992-10-13
ES2112865T3 (es) 1998-04-16
EP0504363B2 (en) 2007-02-07
ATA900791A (de) 1996-06-15
CH681305A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1993-02-26
ZA926191B (en) 1993-04-16
AU2532192A (en) 1993-02-11
GB9209529D0 (en) 1992-07-01
ES2112865T5 (es) 2007-09-16
FI922824A0 (fi) 1992-06-17
CA2069481C (en) 2003-07-29
IL102726A (en) 2002-08-14
HU9202000D0 (en) 1992-10-28
GR910100425A (el) 1992-09-25
IE913560A1 (en) 1992-04-22
EP0504363B1 (en) 1998-01-21
ES2081742A1 (es) 1996-03-01
CH681455A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1993-03-31
AU716402B2 (en) 2000-02-24
AU658926B2 (en) 1995-05-04
AU8729491A (en) 1992-05-20
FI110003B (fi) 2002-11-15
GR3026588T3 (en) 1998-07-31
AU649078B2 (en) 1994-05-12
DE69128774T2 (de) 1998-06-04
FR2677997A1 (fr) 1992-12-24
LU88122A1 (fr) 1993-03-15
GR920100471A (el) 1994-06-30
WO1992007084A1 (en) 1992-04-30
MY119030A (en) 2005-03-31
ITRM910788A0 (it) 1991-10-16
IL102726A0 (en) 1993-01-31
PT100988B (pt) 1999-08-31
HUT64601A (en) 1994-01-28
AU7024294A (en) 1995-01-05
DE69128774D1 (de) 1998-02-26
CA2069481A1 (en) 1992-04-18
JP2638680B2 (ja) 1997-08-06
ITRM910788A1 (it) 1993-04-16
NZ244114A (en) 1995-06-27
FI110002B (fi) 2002-11-15
JPH05504579A (ja) 1993-07-15
MY136210A (en) 2008-08-29
PT99248A (pt) 1993-06-30
FI922380A0 (fi) 1992-05-25
US5644036A (en) 1997-07-01
AU4521897A (en) 1998-02-12
FR2668164A1 (fr) 1992-04-24
FI922380L (fi) 1992-05-25
GB2253397A (en) 1992-09-09
GB9022547D0 (en) 1990-11-28
DE69128774T3 (de) 2007-08-16
DK0504363T3 (da) 1998-09-21
KR960015399B1 (ko) 1996-11-13
NZ240247A (en) 1994-03-25
ATE162552T1 (de) 1998-02-15
TW283710B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1996-08-21
EP0504363A1 (en) 1992-09-23
FR2668164B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1995-04-14
ZA918259B (en) 1993-04-16
FI922824L (fi) 1992-06-17
PT99248B (pt) 1999-04-30

Similar Documents

Publication Publication Date Title
IT1250064B (it) Immunoglobuline purificate, procedimento per la loro purificazione e loro impiego per la preparazione di medicinali.
AR216774A1 (es) Procedimiento para preparar una composicion cosmeticamente aceptable para aplicacion topica a la piel humana
AR229725A1 (es) Composicion acuosa cosmeticamente aceptable para aplicacion topica a la piel humana
NL930118I1 (nl) Ultragezuiverd factor VIII C preparaat
MX9703546A (es) Benzotiazepinas hipolipidemicas.
ES2143978T3 (es) Utilizacion de esteroides para la inhibicion de la angiogenesis.
AU554345B2 (en) Tricyclic antidepressant drug immunogens, antibodies labelled conjugates, and related derivatives
FI914150L (fi) Menetelmä insuliinien puhdistamiseksi kromatografisesti
ES537330A0 (es) Un procedimiento para producir un peptido que comprende un peptido de exo-senal unido operativamente a una proteina deseada
EP0005476A3 (en) Process for preparing human interferon, human interferons prepared by this process and their therapeutical applications
IT8009551A0 (it) E-5-(2-alogenovinil-)-2'deossicitidine, loro metodo di preparazione e loro impiego per il trattamentodi malattie da virus
ES489521A0 (es) Un procedimiento para la preparacion de un peptido
FI945748A7 (fi) Parannukset, jotka kohdistuvat ekstrudoidun tuotteen jatkuvaa muotoilua suorittaviin menetelmiin ja laitteisiin tai liittyvät niihin
DK0700897T3 (da) L-carnitinsalt og kosmetiske og farmaceutiske præparater indeholdende samme til behandling af hudsygdomme
IT1200944B (it) Derivati xantinici,procedimento per la loro preparazione,composizione farmaceutiche che il contengono e loro impiego terapeutico
YU2292A (sh) Antibakterijska sredstva
IT1184285B (it) Derivati steroidei sostituiti in posizione 11-beta,procedimento per la loro preparazione e loro applicazione come medicamenti
PH18734A (en) Panthenol derivatives and their pharmaceutical composition
AU685022B2 (en) Native type II GAP, methods for purifying various GAPs and uses of GAPs to diagnose cancer
FR2751324B1 (fr) Synthese du 1,1,1-trifluoroethane par fluoration du 1-chloro-1,1,-difluoroethane
IT1233005B (it) Anticorpo umano monoclonale, composizione terapeutica che lo contiene linea cellulare capace di produrre l'anticorpo, procedimento per la sua produzione
IT8349055A0 (it) B-osso-l-carbammoil-pirrolpropionitrile, procedimento per la loro produzione, preparati farmaceutici con tenenti questi composti, nonche' il loro impiego terapeutico
IT1096576B (it) Prodotto cosmetico antisolare per il campo uv - a.
FI934468A7 (fi) Bentseeniboorihappojohdannaisia, menetelmä niiden valmistamiseksi ja niiden käyttö synteesin välituotteina
IT8349163A0 (it) 5h-dibenz/b,f/azepin-5-carbossamidi loro prodotti intermedi, preparati farmaceutici che le contengono, procedimento per produrle e loro impiego

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19951027